Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Biologics manufacturers in Asia-Pacific now have a new regional source for the media their cells grow in. Merck's new bioprocessing production center in Daejeon, South Korea, is a 44,500-square-meter site that represents an investment of more than €300 million. It is Merck's largest life science investment in the region to date.

The plant makes the materials a biologics line uses up batch after batch: cell culture media, process liquids, cleaning solutions and sterile sampling gear. Merck is selling proximity. For anyone running supply or quality at a regional biopharma plant, the practical question is which of those materials can now come from inside the region, and at which stage of a product's life.

One site for development and commercial supply

The product list covers more ground than a typical regional warehouse. Daejeon supplies dry powder and liquid cell culture media, including small-scale, custom pre-GMP media through Merck's imMEDIAte ADVANTAGE service. The site's output also includes process liquids, cleaning-in-place solutions that arrive ready to use, and sterile sampling products for single-use processing based on the NovaSeptum Sterile Sampling System. Merck says the media and process liquids use raw materials free of animal-derived components and are made to the same global quality standards it applies across its network.

Jean-Charles Wirth, the Merck Executive Board member who runs the Life Science business, said in the announcement that reliable access to critical materials matters at every stage of biologics manufacturing. He tied Daejeon to supply confidence as customers move from development to commercial scale. CHEManager's report on the opening carries the same framing and the same product list.

The product range at Daejeon runs from pre-GMP small-scale custom media to commercial-scale supply. That suggests a developer in the region could begin with custom batches and scale up on commercial media from the same local site, without switching to a source on another continent partway through.

That would matter most for companies with programs heading toward commercial production in Asia-Pacific. The global-standards claim is what makes it work. A quality team that treats Daejeon lots as equivalent to lots made elsewhere in Merck's network is relying on that consistency, so it's the first thing worth confirming in supplier documentation.

Batch data and a plant without on-site fossil fuels

Two design choices stand out for anyone who audits suppliers. Merck says the center runs an integrated digital system that captures data automatically and traces each batch end to end, which supports quality management and regulatory compliance. Pharma Manufacturing, the trade title that covered the opening under the MilliporeSigma name, describes the systems the same way.

The building is designed to run with no fossil fuels on site. It uses solar power, a heat-pump system, energy recovery in the air handling units and rainwater reuse to cut energy and water consumption. For biopharma companies that ask suppliers about energy use, that gives procurement a specific, documented plant design to point to rather than a corporate pledge.

Where Daejeon sits in Merck's network

Taken together, the moves indicate that Asia-Pacific now has Merck materials production in Korea and expanded biosafety testing in Singapore.

Here's the limit. Daejeon's list doesn't include filtration, which Merck ties to Blarney, and drug product testing sits in Darmstadt. The strategy localizes specific categories, not the whole catalog. A plant whose biggest Merck spend is filters or release testing gets less out of this opening than one that buys media and process liquids by the pallet.

Announced, built and open ahead of schedule

The city is counting on the plant too. Daejeon Mayor Tae-Jeong Heo said the city would commit resources to linking Merck's technologies at the Daedeok Innopolis research district with local companies, universities, research institutes and hospitals, as part of a push to become a global bio hub.

Capacity is the open question. None of the reporting gives designed output or line counts for the 44,500-square-meter site. The clearest sign of how fast Daejeon fills up will be regional manufacturers saying publicly that they've qualified its media for commercial programs.